Trachea project co-funded by
As part of its Regenerative Medicine and Cell Therapy initiative, Innovate UK has awarded Videregen and its project partners UCL and the Cell Therapy Catapult £1.9m develop its lead trachea replacement product through initial clinical trials for the treatment of severe structural airway disease.
The Cell Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK. Their mission is to drive the growth of the industry by helping cell therapy organisations across the world translate early stage research into commercially viable and investable therapies.The Cell Therapy Catapult is working with Videregen to accelerate the clinical and regulatory development of its lead trachea replacement product.
Northwick park Institute for Medical Research (NPIMR) is a leading independent research organisation. As a spin out from NPIMR, Videregen aims to translate their proprietary organ replacement technologies into new therapies to address the chronic shortage of organs for transplantation.
NHSBT is the UK’s major supplier of organs and tissue for transplant and will be responsible for sourcing and consent of deceased tissue donors. The HTA licensed processing facility in Liverpool is the largest of its kind in Europe. The experience and skills of the dedicated team of nurses and scientists within Tissue Services ensures an ethical supply of high quality, UK sourced tissue. Their role is to co-ordinate, recover, process, bank and supply human tissue grafts. The NHSBT has world class staff and facilities for harvesting and processing of donated tissue.
Scientists at the Royal Free London are collaborating with Videregen to develop GMP manufacturing capability for autologous cell seeding of the trachea scaffold. Stem cells will be taken from the patient receiving the transplant and will be used to populate a decellularised donor trachea scaffold.Led by Dr Mark Lowdell, Director of the Paul O’Gorman Laboratory of Cellular Therapeutics, the Royal Free have state-of-the-art GMP manufacture facilities and expertise in stem cell and tissue engineered product manufacture.
University College London (UCL) are collaborating with Videregen for the clinical development of the tissue engineered stem cell seeded trachea replacement product. Led by Professor Martin Birchall, a world renowned ENT/airway surgeon, UCL provide clinical expertise and leadership for the trachea replacement project.